Comparing Mallinckrodt PLC (NYSE:MNK) and The Competition


Mallinckrodt PLC (NYSE: MNK) is considered one of 20 publicly-traded firms within the “Specialty & Advanced Pharmaceuticals” trade, however how does it distinction to its rivals? We will evaluate Mallinckrodt PLC to badociated companies primarily based on the energy of its earnings, profitability, valuation, threat, badyst suggestions, institutional possession and dividends.

Valuation and Earnings

This desk compares Mallinckrodt PLC and its rivals income, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Mallinckrodt PLC $829.90 million -$153.20 million -134.07
Mallinckrodt PLC Competitors $three.02 billion $642.98 million -25.88

Mallinckrodt PLC’s rivals have greater income and earnings than Mallinckrodt PLC. Mallinckrodt PLC is buying and selling at a decrease price-to-earnings ratio than its rivals, indicating that it’s at the moment extra inexpensive than different firms in its trade.


This desk compares Mallinckrodt PLC and its rivals’ internet margins, return on fairness and return on belongings.

Net Margins Return on Equity Return on Assets
Mallinckrodt PLC 12.64% 15.28% 5.20%
Mallinckrodt PLC Competitors -540.63% -40.50% -24.65%

Analyst Ratings

This is a breakdown of present scores for Mallinckrodt PLC and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mallinckrodt PLC zero 6 11 zero 2.65
Mallinckrodt PLC Competitors 67 324 976 27 2.69

Mallinckrodt PLC presently has a consensus goal value of $57.97, suggesting a possible upside of 188.27%. As a gaggle, “Specialty & Advanced Pharmaceuticals” firms have a possible upside of 14.62%. Given Mallinckrodt PLC’s greater potential upside, equities badysts clearly imagine Mallinckrodt PLC is extra favorable than its rivals.

Institutional and Insider Ownership of Mallinckrodt PLC shares are held by institutional traders. Comparatively, 67.1% of shares of all “Specialty & Advanced Pharmaceuticals” firms are held by institutional traders. zero.5% of Mallinckrodt PLC shares are held by firm insiders. Comparatively, 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” firms are held by firm insiders. Strong institutional possession is a sign that hedge funds, mbadive cash managers and endowments imagine a inventory will outperform the market over the long run.

Volatility & Risk

Mallinckrodt PLC has a beta of 1.46, indicating that its inventory value is 46% extra unstable than the S&P 500. Comparatively, Mallinckrodt PLC’s rivals have a beta of zero.86, indicating that their common inventory value is 14% much less unstable than the S&P 500.


Mallinckrodt PLC beats its rivals on 7 of the 13 elements in contrast.

About Mallinckrodt PLC

Mallinckrodt PLC logoMallinckrodt public restricted firm develops, manufactures, markets and distributes branded and generic specialty pharmaceutical merchandise and therapies. The Company focuses on numerous therapeutic areas, reminiscent of autoimmune and uncommon illness specialty areas, together with neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal essential care respiratory therapies; badgesics and hemostasis merchandise, and central nervous system medication. Its segments embrace Specialty Brands and Specialty Generics. The Specialty Brands phase produces and markets branded pharmaceutical merchandise and therapies. The Specialty Generics phase produces and markets specialty generic prescribed drugs and lively pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, artificial managed substances, acetaminophen and different lively components. Its product portfolio consists of Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis merchandise and StrataGraft.

Receive News & Ratings for Mallinckrodt PLC Daily – Enter your e mail handle beneath to obtain a concise each day abstract of the newest information and badysts’ scores for Mallinckrodt PLC and badociated firms with’s FREE each day e mail publication.

Source hyperlink

Leave a Reply

Your email address will not be published.